-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Misses Q4 EPS by 11c
-
-
-
-
-
-
-
CAPR receives FDA request for clinical study report on Deramiocel
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) PT Raised to $54 at Oppenheimer
-
-
-
-
-
-
-
Increasing unusual put option volume: EWC DJX SLG CAPR STNG HUBS ANF URBN DLO WGS KVYO
-
-
-
-
-
-
-
Options with decreasing option implied volatility: CAPR FDX WBD ACN MU LEN
-
-
-
-
-
-
-
Capricor schedules FDA meeting on Deramiocel regulatory path
-
-
-
-
-
-
-
Capricor receives FDA rejection for Duchenne muscular dystrophy treatment
-
427,852 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

